tbuckley/cabot-search huggingface dataset:
Mental health and COVID-19: change the conversation
Authors: None The Lancet Psychiatry
Journal: The Lancet Psychiatry (2020)

"For whosoever hath, to him shall be given, and he shall have more abundance: but whosoever hath not, from him shall be taken away even that he hath." This Biblical verse, Matthew 13:12, provides a rare modern-day example of religion informing science—and Science—in the form of sociologist Robert K Merton's article in a 1968 issue of that prestigious journal. Merton proposed the existence of what he called "The Matthew effect" in scientific research: one that "may serve to heighten the visibility of contributions to science by scientists of acknowledged standing and to reduce the visibility of contributions by authors who are less well known." He added that this principle might apply not only to individual researchers, but also at an institutional level, and hence that "centers of demonstrated scientific excellence are allocated far larger resources for investigation than centers which have yet to make their mark".
Variables associated with personal commitment are the major predictors for early dropouts to a cardiac rehabilitation program Guido Bergman, Balkis Rolong, Ruth Henquin, Luis Guzman, Rosa Zilberberg, Carina Gambarte, Jorge Schneider, Aldo Negri, Melina Huerin. Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Journal: Journal of the American College of Cardiology (2001)
B Cell Function in the Tumor Microenvironment
Authors: Stephanie M. Downs-Canner, Jeremy Meier, Benjamin G. Vincent, Jonathan S. Serody
Journal: Annual Review of Immunology (2022)

The tumor microenvironment (TME) is a heterogeneous, complex organization composed of tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and innate and adaptive immune cells. Over the last decade, it has become increasingly clear that the immune cells in the TME play a critical role in controlling or promoting tumor growth. The function of T lymphocytes in this process has been well characterized. On the other hand, the function of B lymphocytes is less clear, although recent data from our group and others have strongly indicated a critical role for B cells in antitumor immunity. There are, however, a multitude of populations of B cells found within the TME, ranging from naive B cells all the way to terminally differentiated plasma cells and memory B cells. Here, we characterize the role of B cells in the TME in both animal models and patients, with an emphasis on dissecting how B cell heterogeneity contributes to the immune response to cancer.
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment
Authors: Johannes F. Fahrmann, Tracey Marsh, Ehsan Irajizad, Nikul Patel, Eunice Murage, Jody Vykoukal, Jennifer B. Dennison, Kim-Anh Do, Edwin Ostrin, Margaret R. Spitz, Stephen Lam, Sanjay Shete, Rafael Meza, Martin C. Tammemägi, Ziding Feng, Samir M. Hanash
Journal: Journal of Clinical Oncology (2022)

To investigate whether a panel of circulating protein biomarkers would improve risk assessment for lung cancer screening in combination with a risk model on the basis of participant characteristics.
Error in Abstract, Results, and Figure 2 Caption
Journal: JAMA Network Open (2020)

Romesh P. Nalliah, DDS, MHCM; Kenneth R. Sloss, BS; Brooke C. Kenney, MPH; Sarah K. Bettag, BA; Shernel Thomas, BS; Kendall Dubois, MS; Jennifer F. Waljee, MD, MPH; Chad M. Brummett, MD
Evaluation of a novel LOOP-Mediated Amplification system (Illumi-pro 10 Meridian Bioscience Incs), Glutamate Dehydrogenase-GDH (Meridian and Techlab) and a rapid immunoassay- Tox A/B QUIK CHEK (Techlab) for the detection of C. difficile toxin
Journal: Journal of Infection (2011)
TCT-109 Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus™ Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II CE-Mark Study
Authors: Ian T. Meredith, Darren Walters, Nicolas Dumonteil, Stephen G. Worthley, Didier Tchetche, Ganesh Manoharan, Daniel J. Blackman, Gilles Rioufol, David Hildick-Smith, Robert J. Whitbourn, Thierry Lefevre, Ruediger Lange, Ralf Mueller, Simon Redwood, Dominic J. Allocco, Keith D. Dawkins
Journal: Journal of the American College of Cardiology (2015)
Abstract 17339: Maternal Predictors of Disparate Outcomes in Children With Single Ventricle Congenital Heart Disease
Authors: Priyanka Asrani, Nelangi Pinto, Michael Puchalski, Zhining Ou, Cara Heuser, Karen Gibbins, Robert Silver, Erin Zinkhan, Amy Nance, Thomas Miller
Journal: Circulation (2018)

Introduction: Significant variability in morbidity and mortality persists for children with single ventricle congenital heart disease (SV-CHD) despite standardization in medical and surgical care. Multiple risk factors for poor outcomes have been described, but they only explain a fraction of the disparity in outcomes. The Developmental Origins of Health and Disease (DOHaD) theory proposes that fetal adaptation to an adverse in utero environment alters the ability to respond to post-natal stressors and may explain additional risk for poor outcomes. This study assessed maternal risk factor association with disparate outcomes following SV palliation. Hypothesis: Maternal factors related to weight, diabetes, hypertension, and smoking may be associated with an increased risk of poor outcomes in children with SV-CHD. Methods: This retrospective observational cohort study included all term maternal-infant pairs with a diagnosis of SV-CHD who underwent surgical palliation from 2006-2015 at Primary Children’s Hospital. Pairs lacking maternal variables of interest or infant follow-up data up to 1 year were excluded. The association of death or transplant with maternal risk factors [abnormal pre-pregnancy BMI, abnormal weight gain during pregnancy (≤ 7 kg or ≥ 20 kg), any type of hypertension or diabetes and smoking] was analyzed using a multivariable logistic regression model. Results: Of 190 infants who qualified, 135 (71%) maternal-infant dyads had complete data for inclusion. Systemic right ventricular morphology was present in 69% and 31% had systemic left ventricular morphology. Death or transplant occurred in 48 infants (36%) during an average follow-up of 2.2 years (0.1-11.7 years). Abnormal weight gain during pregnancy was present in 34 (25%) mothers, of which 24 had excessive (&gt;20 kg) and 10 had inadequate (&lt;7 kg) weight gain. Prevalence of other risk factors was 53% with an abnormal pre-pregnancy BMI, 10% for diabetes, 6% for hypertension and 8% for smoking. Abnormal weight gain during pregnancy was associated with an increased risk of death or transplant in offspring with SV-CHD. (OR=2.55, 95%CI:1.11-5.84, p=0.027). Conclusions: Abnormal maternal weight gain (excessive or inadequate) during pregnancy is a novel risk factor that may contribute to worse outcomes in SV-CHD.
Deaths
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Comment
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Left ventricular dilation following uncomplicated myocardial infarction in patients with inducible ischemia at discharge Claudio Coletta, Augusto Sestili, Riccardo Rambaldi, Fulvia Seccareccia, Roberto Ricci, Marco Renzi, Nadia Aspromonte, Riccardo Bigi, Alfonso Galati, Vincenzo Ceci. S. Spirito Hospital, Rome, Italy, Cardiovascular Research Foundation, Castelfranco Veneto, Italy
Journal: Journal of the American College of Cardiology (2001)
<scp>COVID</scp>‐19 vaccination uptake in people with severe mental illness: a <scp>UK</scp>‐based cohort study
Authors: Lamiece Hassan, Chelsea Sawyer, Niels Peek, Karina Lovell, Andre F. Carvalho, Marco Solmi, George Tilston, Matthew Sperrin, Joseph Firth
Journal: World Psychiatry (2022)
Pharmacogenomics: Response to aspirin is dose, agonist, and PLA dependent Glen E. Cooke, Yiwen Liu-Stratton, David J. Frid, Raymond D. Magorien, Paul F. Bray, Pascal J. Goldschmidt-Clermont. The Ohio State University, Columbus, OH, Duke University, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Physical training prevented neointimal hyperplasia and inward vascular remodeling after balloon injury and stenting through increased NO signaling Daniele Torella, Ciro Indolfi, Carmela Coppola, Antonio Leccia, Antonio Curcio, Oreste Arcucci, Alfonso Pisani, Giovanni Esposito, Mariacristina Falco, Massimo Chiariello. University Federico II, Naples, Italy, La Magna Graecia University, Catanzaro, Italy
Journal: Journal of the American College of Cardiology (2001)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).
Authors: Eric Van Cutsem, Ken Kato, Jaffer A. Ajani, Lin Shen, Tianyu Xia, Ningning Ding, Lin Zhan, Gisoo Barnes, Sung-Bae Kim
Journal: Journal of Clinical Oncology (2022)

268 Background: RATIONALE 302 was a global phase 3 study (NCT03430843) that investigated tislelizumab (TIS) compared with investigator-chosen chemotherapy (ICC) as second-line treatment for patients (pts) with advanced or metastatic ESCC, in which TIS demonstrated a significant and clinically meaningful improvement in overall survival hazard ratio (HR = 0.70 [95% CI 0.57–0.85], P=0.0001), and a favorable safety profile compared with ICC. Here we assess the HRQoL of pts receiving TIS vs ICC in a pt population that usually experiences HRQoL deterioration. Methods: Adults with advanced or metastatic ESCC whose disease progressed following prior systemic therapy were randomized 1:1 to either TIS 200 mg IV every 3 weeks or ICC (paclitaxel, docetaxel, or irinotecan). HRQoL was measured using the global health status/quality of life (GHS/QoL), physical functioning, and fatigue scores from EORTC QLQ-C30 and the dysphagia, reflux, eating, and pain scores from the EORTC QLQ-OES18 from screening through Cycle 6 or until treatment discontinuation (whichever occurs first) Least-squares mean score change from baseline to Cycles 4 and 6 in HRQoL scores was assessed using a mixed model for repeated measurements. Time to deterioration (TTD) for the GHS/QoL score and the symptom scales of the QLQ-OES18 was examined using the Kaplan-Meier method. Results: Overall, 512 pts (median age 62) were randomized to TIS (n=256) or ICC (n=256). Compared with ICC, TIS-treated pts had stable GHS/QoL and fatigue scores as well as less decline in physical functioning at Cycles 4 and 6 (table). Except for pain, the TIS arm experienced less OES18 symptoms relative to baseline than the ICC arm. TTD analysis showed pts in TIS arm were at lower risk of worsening dysphagia (HR = 0.76 [95% CI 0.53, 1.07], P=0.0562) compared with ICC. Conclusions: The analysis showed that ESCC pts treated with TIS in the second line had a longer maintenance of HRQoL compared to pts treated with ICC. These results, along with improved survival and favorable safety profile, suggest TIS represents a potential new second-line treatment option for pts with advanced or metastatic ESCC. Clinical trial information: NCT03430843.[Table: see text]
The plight of essential workers during the COVID-19 pandemic
Authors: None The Lancet
Journal: The Lancet (2020)

The COVID-19 pandemic has vividly highlighted how much society depends upon essential workers. Praise for the heroic work being done by health-care workers to save lives worldwide in dangerous, exhausting conditions is everywhere. But those same workers are often left unprotected by governments and systems that have failed to supply them with enough personal protective equipment (PPE), supplies, and resources to do their jobs. In April alone, there were an estimated 27 COVID-19-related health worker deaths in the USA, 106 in the UK, and 180 in Russia, with tens of thousands of infections.
Cervical, Not Lumbar
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).
Authors: Inna Markovna Chen, Julia S. Johansen, Susann Theile, Jessica X. Hjaltelin, Sif I. Novitski, Søren Brunak, Jane P. Hasselby, Gro L. Willemoe, Torben Lorentzen, Kasper Madsen, Benny V. Jensen, Eva E. Wilken, Poul F. Geertsen, Claus Behrens, Christian Nolsoe, Kirstine L. Hermann, Inge Marie Svane, Dorte Nielsen
Journal: Journal of Clinical Oncology (2022)

554 Background: Pancreatic ductal adenocarcinoma remains one of the most lethal diseases. Investigating novel treatment strategies for patients with metastatic pancreatic cancer (mPC) is crucial. The purpose of this phase II trial study was to evaluate the clinical benefit of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy (SBRT) in patients with mPC. Methods: Between November 2016 and December 2019, patients with refractory mPC were randomly assigned 1:1 to SBRT of 15 Gy with nivolumab or nivolumab/ipilimumab stratified by performance status. Primary endpoint was clinical benefit rate (CBR) defined as proportion of patients with complete or partial response (PR) or stable disease, according to RECIST 1.1. Simon’s 2-stage phase II optimal design was used independently for both arms with CBR determining expansion to second stage. Secondary endpoints included safety, overall response rate, duration of response (DOR), progression free survival and overall survival (OS). Exploratory analyses included biomarkers related to immune response. Results: Eighty-four patients (41 SBRT/nivolumab and 43 SBRT/nivolumab/ipilimumab) received at least one dose of study treatment. CBR was 17.1% (95% CI, 8.0 to 30.6) for SBRT/nivolumab and 37.2% (95% CI, 24.0 to 52.1) for SBRT/nivolumab/ipilimumab. PR was observed in one patient in SBRT/nivolumab and lasted for 4.6 months. Six patients in SBRT/nivolumab/ipilimumab obtained a PR with a median DOR of 5.4 months (95% CI, 4.2 - not reached). All responders had mismatch repair proficient tumors. Grade 3 or higher treatment-related adverse events occurred in 10 (24.4%) patients in SBRT/nivolumab and in 13 (30.2%) patients in SBRT/nivolumab/ipilimumab. PD-L1 expression by tumor proportion score or combined positivity score of ≥1% was not associated with clinical benefit. On-treatment decrease in serum interleukin (IL)-6, IL-8 and CRP levels was associated with better OS. Conclusions: Clinical meaningful antitumor activity and a manageable safety profile were demonstrated after SBRT/nivolumab/ipilimumab in patients with refractory mPC. Clinical trial information: NCT02866383.
Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Authors: Maria-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, Enrique M. Ocio, Marta Sonia Gonzalez, Albert Oriol, Norma C. Gutierrez, Bruno Paiva, Rafael Rios, Laura Rosinol, Miguel Angel Alvarez, Maria Jose Calasanz, Joan Bargay, Ana Pilar Gonzalez, Adrián Alegre, Fernando Escalante, Rafael Martínez, Noemi Puig, Javier De La Rubia, Ana Isabel Teruel, María Teresa Cedena, Felipe De Arriba, Luis Palomera, Miguel T Hernández, Javier Lopez Jimenez, Jesús Martín, Esther Piensa, Aránzazu García Mateo, Veronica Gonzalez De La Calle, Joan Bladé, Juan Jose Lahuerta, Jesus F San-Miguel
Journal: Blood (2018)
Molecular Biologic and Epidemiologic Insights for Preventability of Colorectal Cancer
Authors: Edward Giovannucci
Journal: JNCI Journal of the National Cancer Institute (2021)

Abstract The etiology of colorectal cancer (CRC) has been informed from both a molecular biology perspective, which concerns the study of the nature, timing, and consequences of mutations in driver genes, and epidemiology, which focuses on identifying risk factors for cancer. For the most part, these fields have developed independently, and it is thus important to consider them in a more integrated manner. The molecular mutational perspective has stressed the importance of mutations due to replication of adult stem cells, and the molecular fingerprint of most CRCs does not suggest the importance of direct carcinogens. Epidemiology has identified numerous modifiable risk factors that account for most CRCs, most of which are not direct mutagens. The distribution of CRCs across the large bowel is not uniform, which is possibly caused by regional differences in the microbiota. Some risk factors are likely to act through or interact with the microbiota. The mutational perspective informs when risk factors may begin to operate in life and when they may cease to operate. Evidence from the mutational model and epidemiology supports that CRC risk factors begin early in life and may contribute to the risk of early-onset CRC. Later in carcinogenesis, there may be a “point of no return” when sufficient mutations have accumulated, and some risk factors do not affect cancer risk. This period may be at least 5-15 years for some risk factors. A more precise knowledge of timing of risk factor to cancer is required to inform preventive efforts.
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
Authors: Rudolf A. de Boer, Stephane Heymans, Johannes Backs, Lucie Carrier, Andrew J.S. Coats, Stefanie Dimmeler, Thomas Eschenhagen, Gerasimos Filippatos, Lior Gepstein, Jean‐Sebastien Hulot, Ralph Knöll, Christian Kupatt, Wolfgang A. Linke, Christine E. Seidman, C. Gabriele Tocchetti, Jolanda van der Velden, Roddy Walsh, Petar M. Seferovic, Thomas Thum
Journal: European Journal of Heart Failure (2021)

Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton, or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology-specific and targeted treatments are lacking. As a result, cardiomyopathies still present a major burden to society, and affect many young and older patients. The Translational Committee of the Heart Failure Association (HFA) and the Working Group of Myocardial Function of the European Society of Cardiology (ESC) organized a workshop to discuss recent advances in molecular and physiological studies of various forms of cardiomyopathies. The study of cardiomyopathies has intensified after several new study setups became available, such as induced pluripotent stem cells, three-dimensional printing of cells, use of scaffolds and engineered heart tissue, with convincing human validation studies. Furthermore, our knowledge on the consequences of mutated proteins has deepened, with relevance for cellular homeostasis, protein quality control and toxicity, often specific to particular cardiomyopathies, with precise effects explaining the aberrations. This has opened up new avenues to treat cardiomyopathies, using contemporary techniques from the molecular toolbox, such as gene editing and repair using CRISPR-Cas9 techniques, antisense therapies, novel designer drugs, and RNA therapies. In this article, we discuss the connection between biology and diverse clinical presentation, as well as promising new medications and therapeutic avenues, which may be instrumental to come to precision medicine of genetic cardiomyopathies.